Actively Recruiting
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
Led by University of Wisconsin, Madison · Updated on 2026-05-05
18
Participants Needed
1
Research Sites
83 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.
CONDITIONS
Official Title
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Pathological diagnosis or suspected epithelial ovarian cancer pending biopsy
- Planned to receive neoadjuvant chemotherapy with carboplatin and paclitaxel or approved alternatives
- May receive bevacizumab and PARP inhibitors as maintenance treatment
- English as primary language
You will not qualify if you...
- History of cognitive impairment or dementia
- History of traumatic brain injury
- Non-primary English speakers
- Uncorrected hearing or visual impairment
- Upper extremity motor impairment affecting cognitive testing
- Baseline Mini Mental State Exam score less than 18
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UW Carbone Cancer Center
Madison, Wisconsin, United States, 53792
Actively Recruiting
Research Team
S
Supportive Oncology
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here